Ken Griffin Mereo Biopharma Group PLC Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.45 - $4.87 $45,885 - $64,771	13,300 Added 13.26%	113,600 $466,000
Q2 2024 Aug 14, 2024	BUY	$2.58 - $4.25 $71,724 - $118,150	27,800 Added 38.34%	100,300 $361,000
Q1 2024 May 15, 2024	BUY	$2.3 - $4.05 $131,330 - $231,255	57,100 Added 370.78%	72,500 $239,000
Q4 2023 Feb 14, 2024	BUY	$1.19 - $2.42 $18,326 - $37,268	15,400 New	15,400 $35,000
Q4 2022 Feb 14, 2023	SELL	$0.5 - $1.01 $9,100 - $18,382	-18,200 Reduced 17.07%	88,400 $66,000
Q3 2022 Nov 14, 2022	BUY	$0.82 - $1.73 $8,774 - $18,511	10,700 Added 11.16%	106,600 $92,000

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $441M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.